Project Grant 1843270

Onc.ai, Inc. received a $1.69M Phase II Small Business Innovation Research (SBIR) award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to further develop and validate a deep learning radiomics biomarker for improved early response assessment in metastatic cancer therapy trials. The company is developing SerialCTRS (Serial CT Response Score), a fully automated deep learning model that analyzes baseline and follow-up computed tomography...

Federal Cooperative Agreement Summary: I-LEARN Study The University of Pennsylvania received a $1.59 million Cooperative Agreement from the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to conduct the Increasing Lung Cancer Screening Effectiveness and Access Through Regional Networks (I-LEARN) study. Awarded September 15, 2025, with completion scheduled for August 31, 2027, this research initiative will compare the effectiveness...

Federal Cooperative Agreement Summary The National Cancer Institute awarded Children's Hospital of Philadelphia $427,064 on July 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct pilot and feasibility studies for a planned randomized controlled trial. This cooperative agreement supports the EDISYN (Early Detection in Syndromic Cancers) Consortium's work to evaluate the addition of circulating tumor DNA (ctDNA) screening to standard cancer screening...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The University of Kentucky Research Foundation a planning grant totaling $281,820 under the Cancer Cause and Prevention Research program (CFDA 93.393) to support development of a future intervention trial designed to improve clinical trial education and enrollment among cancer patients. The award period runs from July 1, 2026, through June 30, 2029. This planning grant funds preparatory work to address persistent...

Sanicka, Inc. was awarded a $793,816 Project Grant from the National Cancer Institute, a component of the Department of Health and Human Services, to develop precision medicine tools for optimizing personalized treatment of patients with acute myeloid leukemia. Under the grant, Sanicka will launch a clinical decision support service called PCITTM Simulator to assist oncologists in simulating disease response and progression for AML patients receiving various chemotherapy, small molecule...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $109,080 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on September 1, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support a Phase II investigator-initiated, multicenter randomized controlled trial (RCT) evaluating predictive markers of response to a novel immunotherapeutic approach in treatment-naive metastatic pancreatic adenocarcinoma (MPDA). The...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $745,458 Project Grant on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to Sloan-Kettering Institute for Cancer Research to develop and implement the PERSON Intervention, an innovative digital health solution designed to enhance person-centered communication in oncology care. The project will operate through June 30, 2031, and delivers three integrated, automated, and scalable...

Federal Cooperative Agreement Summary Award: NSF SBIR Phase II: nCapsule Personalized Cancer Screening for Colorectal Cancer Treatment Regimens Funding Agency: National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) Program (CFDA 47.084) Awardee: Encapsulate Inc., Farmington, Connecticut Award Amount: $1,213,619 | Award Date: June 15, 2025 | Completion Date: May 31, 2027 Encapsulate Inc. is developing an integrated precision oncology platform that combines microfluidics,...

Cooperative Agreement Award Summary Cornell University received a $413,509 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 4, 2025, through July 31, 2028. The award funds development of a deep learning-based 3D network biology knowledge portal to advance precision oncology. The primary deliverable is the PIONEER (Protein-Protein Interaction Interface Prediction) pipeline, a big-data-driven deep...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Ann & Robert H Lurie Children's Hospital of Chicago a $651,859 Project Grant on September 19, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and evaluate #AYAOSM (The AYA Oncology Self-Care Movement), an influencer-driven social media intervention designed to improve oral chemotherapy adherence in adolescents and young adults (AYAs) with acute lymphoblastic leukemia. Prior...